The 36-month beta value for ANAB is also noteworthy at 0.35. There are mixed opinions on the stock, with 9 analysts rating it as a “buy”, 3 rating it as “overweight”, 1 rating it as “hold”, and 0 rating it as “sell”.
The public float for ANAB is 25.82M, and at present, short sellers hold a 21.94% of that float. The average trading volume of ANAB on February 12, 2026 was 522.54K shares.
ANAB stock’s latest price update
The stock of AnaptysBio Inc (NASDAQ: ANAB) has increased by 9.97% when compared to last closing price of $50.24.Despite this, the company has seen a gain of 14.20% in its stock price over the last five trading days.
ANAB’s Market Performance
AnaptysBio Inc (ANAB) has experienced a 14.20% rise in stock performance for the past week, with a 12.69% rise in the past month, and a 62.60% rise in the past quarter. The volatility ratio for the week is 8.73%, and the volatility levels for the past 30 days are at 6.83% for ANAB. The simple moving average for the past 20 days is 13.59% for ANAB’s stock, with a 76.59% simple moving average for the past 200 days.
Analysts’ Opinion of ANAB
Many brokerage firms have already submitted their reports for ANAB stocks, with UBS repeating the rating for ANAB by listing it as a “Buy”. The predicted price for ANAB in the upcoming period, according to UBS is $70 based on the research report published on January 07, 2026 of the current year 2026.
Barclays, on the other hand, stated in their research note that they expect to see ANAB reach a price target of $78. The rating they have provided for ANAB stocks is “Overweight” according to the report published on October 13th, 2025.
Wolfe Research gave a rating of “Outperform” to ANAB, setting the target price at $25 in the report published on February 04th of the previous year.
ANAB Trading at 17.34% from the 50-Day Moving Average
After a stumble in the market that brought ANAB to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.30% of gains for the given period.
Volatility was left at 6.83%, however, over the last 30 days, the volatility rate increased by 8.73%.
Insider Trading
Marquet Magda, the Director of AnaptysBio Inc, sale 11,000 shares at $48.23 during a trade that took place back on Jan 15 ’26, which means that Marquet Magda is holding 9,930 shares at $530,531 based on the most recent closing price.
Stock Fundamentals for ANAB
Current profitability levels for the company are sitting at:
- -0.17% for the present operating margin
- 0.1% for the gross margin
The net margin for AnaptysBio Inc stands at -0.5%. The total capital return value is set at -0.09%. Equity return is now at value -308.02%, with -19.99% for asset returns.
Based on AnaptysBio Inc (ANAB), the company’s capital structure generated 1.09 points at debt to capital in total, while cash flow to debt ratio is standing at -0.42. The debt to equity ratio resting at -11.78. The interest coverage ratio of the stock is -0.37.
Currently, EBITDA for the company is -$92.74 million with net debt to EBITDA at -51.78. When we switch over and look at the enterprise to sales, we see a ratio of 10.42. The receivables turnover for the company is 2.24for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.68.
Conclusion
In summary, AnaptysBio Inc (ANAB) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.